THERAPY DOSSIER · th-c5b2a3a5f2b0

Human cord blood-derived hepatic progenitors combined with a selected mix of hepatogenic factors

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT04522869 ↗PHASE1/PHASE2completed

Evaluation Safety and Efficacy of Umbilical Cord Derived Mesenchymal Stem Cell Transplantation for Children Suffering From Liver Cirrhosis Due to Biliary Atresia

Primary Biliary Cirrhosis

Enrolment: 20 · Results not recorded

NCT04234412 ↗NAunknown

Treatment of Osteoarthritic Knee With High Tibial Osteotomy and Implantation of Allogenic Human Umbilical Cord Blood-derived Stem Cells

Osteoarthritis, Knee

Enrolment: 10 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30942524 ↗2019Reported benefit

Combination of cord blood-derived human hepatic progenitors and hepatogenic factors strongly improves recovery after acute liver injury in mice through modulation of the Wnt/beta-catenin signaling.

MouseOtherSCIDMale

Model: Acute liver injury model in mice

Combining human hepatic progenitors with hepatogenic factors improved engraftment, triggered Wnt/beta-catenin signalling, accelerated the regenerative process and improved rescue of hepatic function compared with hepatogenic factors alone.

Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…